• Home
  • News
2021-09-28 | views:1247
테라젠바이오•엔에이백신연구소, 항암백신 개발 협력
2021-09-23 | views:1117
"게임ㆍ앱으로 조현병, 고혈압 치료"…‘디지털 치료제’ 상용화 속도
2021-08-31 | views:2182
Through CEO of Hanmi Science, CancerRop Issues KRW 20 Billion New Shares for Cooperation with Oxford Vacmedix
2021-08-31 | views:1385
인천경제청 바이오헬스 비즈니스 생태계 조성 총력
2021-08-30 | views:1026
FDA, 뇌졸증 회복 돕는 '디지털 치료제' 승인
2021-08-26 | views:814
코로나19로 디지털치료제 수요 ↑…美 FDA, 올해만 6개 허가
2021-08-25 | views:2690
Hanmi Science consortium aims to be Asia-Pacific region’s vaccine hub
2021-08-18 | views:1275
에스티팜, 테라젠바이오와 ‘mRNA 항암백신’ 연구개발 나선다
2021-08-17 | views:2217
Hanmi Science has completed the development of six types of raw materials for mRNA vaccines
  1.   
  2. 38
  3. 39
  4. 40
  5. 41
  6. 42
  7. 43
  8. 44
  9.   
  • 10F, 173, Digital-ro, Geumcheon-gu, Seoul (Gasan-dong, Elysian)
  • Tel : 02-890-8700
  • IR Service : 02-6964-8770
  • Fax : 02-6964-8755

About Us

Goals & Promise

Leadership

Company History

IR

Notice & IR

Disclosure Information

Dx&Vx 2023 Award Impact

Contact

Private Policy Terms of Use twitter icon @dxvx_official
© 2024 Dx&Vx. All Rights Reserved.